Auris Medical Holding AG (NASDAQ:EARS) shares saw strong trading volume on Thursday . 73,585 shares changed hands during mid-day trading, a decline of 6% from the previous session’s volume of 77,925 shares.The stock last traded at $3.68 and had previously closed at $3.65.

A number of equities analysts have recently weighed in on the company. Zacks Investment Research raised Auris Medical Holding AG from a “hold” rating to a “buy” rating and set a $4.50 price target for the company in a report on Tuesday. Leerink Swann reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Auris Medical Holding AG in a research report on Wednesday, June 15th. Finally, Jefferies Group reaffirmed a “buy” rating on shares of Auris Medical Holding AG in a research report on Friday, June 10th.

The stock’s market capitalization is $128.05 million. The stock’s 50 day moving average price is $3.83 and its 200-day moving average price is $4.10.

Auris Medical Holding AG (NASDAQ:EARS) last issued its quarterly earnings results on Wednesday, May 11th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by $0.04. During the same quarter in the previous year, the company earned ($0.28) earnings per share. On average, analysts forecast that Auris Medical Holding AG will post ($1.01) EPS for the current year.

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.